Open Access
Subscription Access
Open Access
Subscription Access
Convalescent Plasma Therapy: How Man Survived through the Centuries
Subscribe/Renew Journal
Since historical times passive immune therapy played key role in disease prevention and control in absence of vaccine. Convalescent whole blood, convalescent plasma (CP), pooled human immunoglobin, etc. were applied as the last resource available at that moment to the critically ill patients. This method had always been adopted when the pathogen was new and regular therapeutic measures were ineffective to defend the pathogen. CP has shown its efficacy through the centuries during outbreak of Spanish Influenza, West African Ebola, West Nile virus, MERS-CoV, SARS-CoV-1, H1N1, etc.
Keywords
WHO, NAT, COVID-19, RT-PCR, ELISA.
User
Subscription
Login to verify subscription
Font Size
Information
- J A Owen, J Punt, S A Strandford, P P Jones and J Kuby, Kuby Immunology, New York Publisher, 7th Edition.
- www.hematology.org accessed on 22.07.2020.
- A Casadevall and L Pirofski,The convalescent sera option for containing COVID-19 Arturo, The Journal of Clinical Investigation, American Society for Clinical Investigation, Vol 130, No 4, page 1545-1548, 2020.
- www.cdc.gov accessed on 22.07.2020.
- www.who.int accessed on 22.07.2020.
- 6. Y Cheng, R Wong, Y O Y Soo, W S Wong, C K Lee, M H L Ng, P Chan, K C Wong, C B Leung and G Cheng, Use of convalescent plasma therapy in SARS patients in Hong Kong, European Journal of Clinical Microbiology and Infectious Diseases, Springer, Vol 24, page 44–46, 2005.
- J van Griensven, T Edwards, X de Lamballerie, M G Semple, P Gallion, S Baize, P W Horby, H Raoul, N Magassouba et al., Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea, New England Journal of Medicine, NEJM Group, Vol 374, page 33-42, 2016.
- Y Arabi, H Balkhy, A H Hajeer, A Bouchama, F G Hayden, A Al‑Omari, F M Al‑Hameed et al., Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol, SpringerPlus, Springer, Vol 4, No 709, page 1490-1409, 2015.
- K Duan, B Liu, C Li, H Zhang, T Yu, J Qu, M Zhou et al., The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study, medRxiv, Cold Spring Harbour Laboratory, https://doi.org/10.1101/2020.03.16.20036145, 2020.
- T Burnouf and J Seghatchian, Ebola virus convalescent blood products: Where we are now and where we may need to go, Transfusion and Apheresis Science, Elsevier, Vol 51, No 2, page 120-125, 2014.
- www.who.int/Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks, Interim guidance for national health authorities and blood transfusion services, Geneva, World Health Organization, September 2014.
- www.cdsco.gov.in/notice dated 17.04.20.
- https://www.fda.gov/vaccines-bloodbiologics/investigational-new-drug-ind-or-device-exemption-ide-processcber/recommendations-investigationalcovid-19-convalescent-plasma, US Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma, FDA, 2020.
- https://cdsco.gov.in/Drugs and Cosmetics Act 1940 and Rules 1945, amended 2020.
- L Du, Y He, Y Zhou, S Liu, B-J Zheng and S Jiang, The spike protein of SARS-CoV–a target for vaccine and therapeutic development, Nature Reviews Microbiology, Nature, Vol 7, page 226-236, 2009.
- X Tian, C Li, A Huang, S Xia, S Lu, Z Shi et al., Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody, Emerging Microbes and Infection, Tailor and Francis, Vol 9, No 1, page 382-385, 2020.
- F Wu, A Wang, M Liu, Q Wang, J Chen, S Xia et al., Neutralizing antibody responses to SARSCoV2 in a COVID-19 recovered patient cohort and their implications, MedRxiv, Cold Spring Harbour Laboratory, 2020, https://doi.org/10.1101/2020.03.30.20047365.
- M Rojasa, Y Rodrígueza, D M Monsalvea, Y Acosta-Ampudiaa, B Camachoc, J E Gallod et al., Convalescent plasma in Covid-19: Possible mechanisms of action , Autoimmunity Reviews, Science Direct, Vol 19, Issue 7, page 102554 (9), 2020.
- K Duan, B Liu, C Li, H Zhang, T Yu, J Qu et al., Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proceedings of the National Academy of Sciences of the United States of America, National Academy of Sciences, Vol 117, No 17, page 9490-9496, 2020.
Abstract Views: 238
PDF Views: 0